{"id":1248,"date":"2025-09-10T10:00:07","date_gmt":"2025-09-10T08:00:07","guid":{"rendered":"https:\/\/www.dgrpharma.com\/?p=1248"},"modified":"2025-09-10T09:21:59","modified_gmt":"2025-09-10T07:21:59","slug":"dgr-pharma-acquired-by-symeres","status":"publish","type":"post","link":"https:\/\/www.dgrpharma.com\/cms19\/dgr-pharma-acquired-by-symeres\/","title":{"rendered":"DGr Pharma Acquired by Symeres"},"content":{"rendered":"<div>We are delighted to announce the acquisition of DGr Pharma, by <a href=\"https:\/\/symeres.com\/\">Symeres<\/a>, a mid-sized, transatlantic contract research and development organisation (CRO\/CDMO) specialising in small-molecule drug discovery and development.<\/div>\n<div><br class=\"avia-permanent-lb\" \/><br class=\"avia-permanent-lb\" \/><\/div>\n<div><a href=\"https:\/\/symeres.com\/wp-content\/uploads\/2025\/09\/DGr-Pharma-Acquisition-Press-Release-September-2025-3.pdf\">Download Press Release<\/a><\/div>\n<div><\/div>\n<div><br class=\"avia-permanent-lb\" \/>With headquarters in the Netherlands and operations across Europe and the United States, Symeres offers over 30 years of industry experience and serves biotech and pharmaceutical clients worldwide.<\/div>\n<div>Symeres provides end-to-end R&amp;D services, bridging early discovery to clinical drug substance manufacturing. Their offering spans:<\/div>\n<div><\/div>\n<ul>\n<li>Drug Discovery &amp; Medicinal Chemistry<br \/>\n\u2013 Hit finding, lead optimisation, rapid analog synthesis, computational chemistry.<\/li>\n<li>Enabling Technologies<br \/>\n\u2013 Biocatalysis, flow chemistry, photochemistry, PROTACs, macrocycles, and other advanced chemistry solutions.<\/li>\n<li>ADME-Tox \/ DMPK (via <a href=\"https:\/\/admescope.com\/\">Admescope<\/a>)<br \/>\n\u2013 In vitro and in vivo pharmacokinetics, metabolism studies, permeability, and toxicology profiling.<\/li>\n<li>CMC &amp; Drug Development<br \/>\n\u2013 Process R&amp;D, analytical development, formulation, solid-state chemistry, stability studies.<\/li>\n<li>Manufacturing<br \/>\n\u2013 Non-GMP scale-up for IND-enabling studies and GMP manufacturing for clinical supplies.<\/li>\n<li>Biology &amp; Oncology (via <a href=\"https:\/\/www.oncolines.com\/\">Oncolines<\/a>)<br \/>\n\u2013 Cell-line panels, biomarker discovery, immuno-oncology assays.<\/li>\n<\/ul>\n<div><\/div>\n<div>With this acquisition, our consultancy and regulatory expertise will become part of Symeres\u2019 integrated offering, extending support further along the development pathway. Together, we strengthen the ability to guide clients seamlessly from early discovery through development, registration, and manufacturing.<\/div>\n<div><\/div>\n<div>This partnership reflects a shared commitment to building a truly end-to-end service model. By combining our strengths, we will deliver even greater flexibility, scientific depth, and speed\u2014helping clients bring high-quality medicines to patients worldwide.<\/div>\n<div><\/div>\n<div><\/div>\n<div>We look forward to working closely with our new colleagues and building the next chapter of DGr Pharma together.<\/div>\n<div><\/div>\n","protected":false},"excerpt":{"rendered":"<p>We are delighted to announce the acquisition of DGr Pharma, by Symeres, a mid-sized, transatlantic contract research and development organisation (CRO\/CDMO) specialising in small-molecule drug discovery and development. Download Press Release With headquarters in the Netherlands and operations across Europe and the United States, Symeres offers over 30 years of industry experience and serves biotech [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":1249,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"class_list":["post-1248","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/www.dgrpharma.com\/cms19\/wp-json\/wp\/v2\/posts\/1248","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.dgrpharma.com\/cms19\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.dgrpharma.com\/cms19\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.dgrpharma.com\/cms19\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.dgrpharma.com\/cms19\/wp-json\/wp\/v2\/comments?post=1248"}],"version-history":[{"count":11,"href":"https:\/\/www.dgrpharma.com\/cms19\/wp-json\/wp\/v2\/posts\/1248\/revisions"}],"predecessor-version":[{"id":1283,"href":"https:\/\/www.dgrpharma.com\/cms19\/wp-json\/wp\/v2\/posts\/1248\/revisions\/1283"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.dgrpharma.com\/cms19\/wp-json\/wp\/v2\/media\/1249"}],"wp:attachment":[{"href":"https:\/\/www.dgrpharma.com\/cms19\/wp-json\/wp\/v2\/media?parent=1248"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.dgrpharma.com\/cms19\/wp-json\/wp\/v2\/categories?post=1248"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.dgrpharma.com\/cms19\/wp-json\/wp\/v2\/tags?post=1248"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}